Posted by Michael Wonder on 09 Aug 2024
PHARMAC indicates interest in funding cancer treatment bevacizumab
9 August 2024 - PHARMAC is seeking commercial bids from suppliers for the supply of bevacizumab for a range of cancers.
“Today, we have issued a future procurement opportunity (FPO) for the cancer treatment bevacizumab,” says PHARMNAC’s Chief Medical Officer, Dr David Hughes.
“This is a preliminary stage in government procurement that signals to the supplier market and New Zealanders that we are interested in considering funding bevacizumab for a range of indications.
